V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003242 | 210011552 | 1.6 | 75.6 | Neo-adjuvant (N) | 2018-09-16 | 2018-10-01 | Vinorelbine (oral) | null | N | VINORELBINE | 101596185 |
| 210003260 | 210011558 | 1.58 | 71 | Palliative (P) | 2017-04-01 | 2017-04-01 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101642636 |
| 210003263 | 210011560 | 1.57 | 68.4 | Neo-adjuvant (N) | 2018-09-20 | 2018-12-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | ATEZOLIZUMAB | 101824256 |
| 210003269 | 210011561 | 1.48 | 68.4 | Adjuvant (A) | 2021-04-10 | 2021-04-11 | PERTUZUMAB + TRASTUZUMAB | null | null | PERTUZUMAB + TRASTUZUMAB | 100582502 |
| 210003270 | 210011562 | null | null | null | null | 2017-08-01 | null | 02 | null | FULVESTRANT + RIBOCICLIB | 100006670 |
| 210003273 | 210011564 | null | 71.35 | null | 2018-11-14 | 2019-07-02 | CMF | null | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101807706 |
| 210003277 | 210011566 | 1.48 | 55.6 | Palliative (P) | 2018-07-14 | 2019-11-11 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100163578 |
| 210003278 | 210011567 | 1.54 | 56.7 | Neo-adjuvant (N) | null | 2018-12-23 | Pertuzumab (Loading) | 02 | N | PERTUZUMAB | 100603073 |
| 210003282 | 210011568 | 1.62 | 66 | Palliative (P) | 2018-04-30 | 2018-04-30 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100093197 |
| 210003284 | 210011570 | 1.65 | 65.3 | Palliative (P) | 2016-04-04 | 2016-06-12 | Capecitabine | 02 | N | CAPECITABINE | 101831786 |
| 210003287 | 210011571 | 1.65 | 61.8 | Curative (C) | 2018-09-15 | 2018-12-01 | Abemaciclib | 02 | N | TRIAL UNSPECIFIED | 100051775 |
| 210003293 | 210011572 | 1.54 | 62.8 | Neo-adjuvant (N) | null | 2019-07-16 | Eribulin | null | N | ERIBULIN | 101260674 |
| 210003295 | 210011573 | 0 | 92.7 | Neo-adjuvant (N) | 2020-03-06 | 2020-04-04 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101706298 |
| 210003296 | 210011574 | null | null | null | 2020-03-03 | 2020-05-23 | Carboplatin AUC 6 - 10 | 02 | null | CARBOPLATIN | 100768044 |
| 210003299 | 210011576 | 1.56 | 69.4 | Palliative (P) | 2019-05-15 | 2019-08-26 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101705452 |
| 210003302 | 210011578 | 1.74 | 59.2 | Neo-adjuvant (N) | 2019-11-17 | 2019-11-18 | Letrozole + Palbociclib | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100588109 |
| 210003304 | 210011579 | 1.68 | 94.8 | Adjuvant (A) | 2021-03-08 | 2021-03-20 | null | 01 | N | PALBOCICLIB | 100561238 |
| 210003309 | 210011580 | 1.5 | 67 | null | null | 2019-04-06 | null | null | null | ROSCO TRIAL | 100412354 |
| 210003311 | 210011581 | 1.57 | 80.4 | Neo-adjuvant (N) | 2018-04-07 | 2020-12-10 | Eribulin | null | N | ERIBULIN | 101800626 |
| 210003312 | 210011582 | 1.65 | 79.45 | Neo-adjuvant (N) | 2018-08-07 | 2018-08-07 | null | 02 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100032054 |
| 210003313 | 210011583 | 1.57 | 127 | Adjuvant (A) | 2018-05-22 | 2018-06-05 | Capecitabine | 02 | N | CAPECITABINE | 101271455 |
| 210003314 | 210011584 | 0 | 77.2 | Palliative (P) | 2019-11-19 | 2020-04-27 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100408927 |
| 210003315 | 210011585 | 1.52 | 49 | Adjuvant (A) | 2022-01-23 | 2022-03-30 | null | null | N | TRIAL UNSPECIFIED | 101120071 |
| 210003319 | 210011586 | null | null | null | null | 2020-07-17 | Vinorelbine (oral) | null | null | VINORELBINE | 100875292 |
| 210003325 | 210011587 | null | null | null | 2020-05-27 | 2020-09-18 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100793026 |
| 210003326 | 210011588 | 0 | 79.5 | Palliative (P) | 2019-08-20 | 2019-09-11 | Carboplatin + Docetaxel | 02 | N | CARBOPLATIN + DOCETAXEL | 101671812 |
| 210003328 | 210011589 | null | 72 | null | 2019-09-11 | 2019-09-11 | GemCarbo Days 1+8 | 02 | null | NAB-PACLITAXEL | 101346546 |
| 210003331 | 210011590 | 1.58 | 81.8 | null | null | 2020-11-17 | ATEZOLIZUMAB + NAB PACLITAXEL | null | null | ABEMACICLIB + FULVESTRANT | 101718877 |
| 210003332 | 210011591 | null | null | null | null | 2019-09-02 | TCH (21 day Trastuzumab) Maint | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101530185 |
| 210003333 | 210011592 | 0.94 | 64.3 | null | null | 2019-11-12 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100273998 |
| 210003334 | 210011593 | 1.69 | 60.5 | Palliative (P) | null | 2019-01-28 | null | null | N | LETROZOLE + PALBOCICLIB | 100478602 |
| 210003336 | 210011594 | null | 62.7 | null | null | 2017-06-24 | Trial Unspecified | 02 | null | FULVESTRANT + PALBOCICLIB | 100446841 |
| 210003338 | 210011595 | 1.58 | 49.7 | Adjuvant (A) | 2016-09-22 | 2016-10-05 | Vinorelbine (oral) | 02 | N | VINORELBINE | 101047007 |
| 210003339 | 210011596 | null | 70.5 | null | null | 2017-03-11 | Capecitabine | 02 | null | CAPECITABINE | 101171326 |
| 210003342 | 210011598 | 1.55 | 60.7 | Palliative (P) | 2021-11-17 | 2021-11-17 | Capecitabine | 02 | N | CAPECITABINE | 100510666 |
| 210003344 | 210011599 | 1.61 | 77.4 | null | 2018-02-12 | 2018-02-22 | Eribulin | 02 | null | ERIBULIN | 100143902 |
| 210003348 | 210011600 | 1.68 | 57.5 | Neo-adjuvant (N) | 2020-10-12 | 2021-02-12 | Doce + Pertuzumab + Trastuz IV Load | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100405639 |
| 210003351 | 210011601 | 1.72 | 81.8 | null | 2022-02-14 | 2022-03-01 | Eribulin | 02 | null | ERIBULIN | 101572905 |
| 210003352 | 210011602 | 1.74 | 0 | null | 2017-02-03 | 2017-02-03 | Carboplatin AUC 6 - 10 | 02 | null | CARBOPLATIN | 100260471 |
| 210003353 | 210011603 | 1.67 | 76.1 | Neo-adjuvant (N) | 2018-12-16 | 2019-03-13 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100093309 |
| 210003354 | 210011604 | 1.57 | 137.8 | Adjuvant (A) | 2018-10-31 | 2019-01-18 | CARBOPLATIN | 02 | N | FEC | 101398167 |
| 210003355 | 210011605 | 1.48 | 92.5 | Palliative (P) | 2020-04-29 | 2020-04-29 | Eribulin | 02 | N | ERIBULIN | 100255752 |
| 210003358 | 210011608 | 1.57 | 73 | null | null | 2016-11-02 | Trial Unspecified | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 100534008 |
| 210003359 | 210011609 | 1.58 | 59.3 | Adjuvant (A) | 2013-03-09 | 2013-03-11 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101038709 |
| 210003361 | 210011610 | 0 | 89.2 | Neo-adjuvant (N) | 2017-01-01 | 2017-01-22 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 02 | N | LETROZOLE + PALBOCICLIB | 100315102 |
| 210003364 | 210011611 | 1.53 | 92.1 | Adjuvant (A) | 2017-04-08 | 2017-04-16 | Trial Unspecified | 02 | N | TRASTUZUMAB EMTANSINE | 100922596 |
| 210003367 | 210011612 | 1.52 | 62 | Curative (C) | 2019-06-05 | 2019-07-03 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101819454 |
| 210003370 | 210011613 | 1.73 | 85.4 | null | 2020-04-17 | 2020-04-29 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100300042 |
| 210003371 | 210011614 | 1.72 | 72.5 | null | 2018-02-07 | 2018-04-27 | Capecitabine | null | null | CAPECITABINE | 101027926 |
| 210003374 | 210011616 | 1.69 | 113.8 | null | null | 2019-03-10 | CYCLOPHOSPHAMIDE + DOXORUBICIN | null | null | TRASTUZUMAB EMTANSINE | 100104750 |